BOUNDLESS BIO, INC. Comprehensive Income
BOUNDLESS BIO, INC. (BOLD) reported Comprehensive Income of -$23.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-07
- BOUNDLESS BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$23.70M.
- BOUNDLESS BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$13.64M.
- BOUNDLESS BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$12.87M.
- BOUNDLESS BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$13.82M.
- BOUNDLESS BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$58.25M.
- BOUNDLESS BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$65.28M.
- BOUNDLESS BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$49.00M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$23.70M 10-Q · filed 2026-08-07 | -$37.34M 10-Q · filed 2026-08-07 | -$50.22M derived: sum of 3 quarters · filed 2026-08-07 | -$64.04M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$13.64M 10-Q · filed 2026-05-08 | -$26.51M derived: sum of 2 quarters · filed 2026-05-08 | -$40.34M derived: sum of 3 quarters · filed 2026-05-08 | -$56.05M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$12.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$26.70M derived: sum of 2 quarters · filed 2026-03-09 | -$42.41M derived: sum of 3 quarters · filed 2026-08-07 | -$58.25M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$13.82M 10-Q · filed 2025-11-05 | -$29.54M derived: sum of 2 quarters · filed 2026-08-07 | -$45.38M 10-Q · filed 2025-11-05 | -$61.95M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$15.71M 10-Q · filed 2026-08-07 | -$31.56M 10-Q · filed 2026-08-07 | -$48.12M derived: sum of 3 quarters · filed 2026-08-07 | -$64.33M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$15.85M 10-Q · filed 2026-05-08 | -$32.41M derived: sum of 2 quarters · filed 2026-05-08 | -$48.62M derived: sum of 3 quarters · filed 2026-05-08 | -$65.64M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$16.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$32.77M derived: sum of 2 quarters · filed 2026-03-09 | -$49.79M derived: sum of 3 quarters · filed 2026-03-09 | -$65.28M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$16.21M 10-Q · filed 2025-11-05 | -$33.23M derived: sum of 2 quarters · filed 2025-11-05 | -$48.72M 10-Q · filed 2025-11-05 | -$60.71M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$17.02M 10-Q · filed 2025-08-05 | -$32.51M 10-Q · filed 2025-08-05 | -$44.50M derived: sum of 3 quarters · filed 2025-08-05 | -$57.65M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$15.49M 10-Q · filed 2025-05-09 | -$27.48M derived: sum of 2 quarters · filed 2025-05-09 | -$40.63M derived: sum of 3 quarters · filed 2025-05-09 | -$53.05M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$11.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$25.14M derived: sum of 2 quarters · filed 2025-03-27 | -$37.55M derived: sum of 3 quarters · filed 2025-03-27 | -$49.00M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$13.15M 10-Q · filed 2024-11-07 | -$25.57M derived: sum of 2 quarters · filed 2024-11-07 | -$37.01M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$12.42M 10-Q · filed 2024-08-12 | -$23.86M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | -$11.44M 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |